TURBO OPTIONSSCHEIN - VIVORYON THERAPEUTICS | Real-time Bid/Ask 04:16:04 2024-06-13 am EDT | ||
| 2.02 EUR / 2.08 EUR | -7.66% |
|
| Current month | +37.42% | ||
| 1 month | +918.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VIVORYON THERAPEUTICS N.V.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-13 | 2.1 | -5.41% |
| 24-06-12 | 2.24 | +0.90% |
| 24-06-11 | 2.22 | -2.20% |
| 24-06-10 | 2.27 | -4.62% |
| 24-06-07 | 2.38 | -5.93% |
Delayed Quote Börse Stuttgart
Last update June 13, 2024 at 02:11 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VIVORYON THERAPEUTICS N.V. |
| Issuer | Lang & Schwarz |
| WKN | LX34JU |
| ISIN | DE000LX34JU2 |
| Date issued | 2024-04-24 |
| Strike | 0.6 € |
| Maturity | 2024-12-12 (183 Days) |
| Parity | 1 : 1 |
| Emission price | 0.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.15 € |
|---|---|
| Lowest since issue | 0.07 € |
| Spread | 0.06 € |
| Spread % | 2.86% |
Company Profile
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Sector
-
Consensus: Vivoryon Therapeutics N.V.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.44
EUR
Average target price
41.57
EUR
Spread / Average Target
+1,603.55%
- Stock Market
- Certificates
- Certificat
